WASHINGTON (AP) — Amylin Pharmaceuticals Inc. (Nasdaq:AMLN) has won approval from the U.S. Food and Drug Administration (FDA) for Bydureon, an injectable diabetes drug that will cost patients and their insurers 11% more than an older version of the drug, Byetta, but is more convenient.
Patients with type 2 diabetes can control their blood by taking Bydureon just once a week, according to Amylin, San Diego. Users of Byetta, which is 7 years old, must inject that drug twice a day.
The monthly cost of a series of injections could be $323 for Bydureon, compared with $291 for Byetta.
Amylin has faced delays in getting FDA approval for Bydureon, and the diabetes drug market now includes a treatement in the same class that has shown superior results.
What Your Peers Are Reading
Bydureon is part of the GLP-1 class of drugs, which work by increasing the body’s insulin production.